244 related articles for article (PubMed ID: 30314910)
1. An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model.
Bockstal V; Tiemessen MM; Achterberg R; Van Wordragen C; Knaapen AM; Serroyen J; Marissen WE; Schuitemaker H; Zahn R
Vaccine; 2018 Nov; 36(46):6979-6987. PubMed ID: 30314910
[TBL] [Abstract][Full Text] [Related]
2. Production of high titer attenuated poliovirus strains on the serum-free PER.C6(®) cell culture platform for the generation of safe and affordable next generation IPV.
Sanders BP; Oakes Ide L; van Hoek V; Liu Y; Marissen W; Minor PD; Wimmer E; Schuitemaker H; Custers JH; Macadam A; Cello J; Edo-Matas D
Vaccine; 2015 Nov; 33(48):6611-6. PubMed ID: 26529068
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of experimental stand-alone trivalent, inactivated Sabin-strain polio vaccine formulations in healthy infants: A randomized, observer-blind, controlled phase 1/2 trial.
Cramer JP; Jimeno J; Han HH; Lin S; Hartmann K; Borkowski A; Sáez-Llorens X
Vaccine; 2020 Jul; 38(33):5313-5323. PubMed ID: 32563609
[TBL] [Abstract][Full Text] [Related]
4. Surveillance of immunity acquired from poliovirus immunization including vaccination with the Sabin strain-derived inactivated vaccine.
Hotta C; Ogawa T; Shirasawa H
Hum Vaccin Immunother; 2019; 15(5):1154-1159. PubMed ID: 30676843
[TBL] [Abstract][Full Text] [Related]
5. Differences in Antigenic Structure of Inactivated Polio Vaccines Made From Sabin Live-Attenuated and Wild-Type Poliovirus Strains: Impact on Vaccine Potency Assays.
Crawt L; Atkinson E; Tedcastle A; Pegg E; ; Minor P; Cooper G; Rigsby P; Martin J
J Infect Dis; 2020 Feb; 221(4):544-552. PubMed ID: 30788503
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age.
Ong-Lim AL; Shukarev G; Trinidad-Aseron M; Caparas-Yu D; Greijer A; Duchene M; Scheper G; van Paassen V; Le Gars M; Cahill CP; Schuitemaker H; Douoguih M; Jacquet JM
Hum Vaccin Immunother; 2022 Nov; 18(5):2044255. PubMed ID: 35344464
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial.
He H; Wang Y; Deng X; Yue C; Tang X; Li Y; Liu Y; Yin Z; Zhang G; Chen Z; Xie S; Wen N; An Z; Chen Z; Wang H
Lancet Infect Dis; 2020 Sep; 20(9):1071-1079. PubMed ID: 32442523
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults.
Leroux-Roels I; Leroux-Roels G; Shukarev G; Schuitemaker H; Cahill C; de Rooij R; Struijs M; van Zeeburg H; Jacquet JM
Hum Vaccin Immunother; 2021 May; 17(5):1366-1373. PubMed ID: 33175637
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults.
Verdijk P; Rots NY; van Oijen MG; Oberste MS; Boog CJ; Okayasu H; Sutter RW; Bakker WA
Vaccine; 2013 Nov; 31(47):5531-6. PubMed ID: 24063976
[TBL] [Abstract][Full Text] [Related]
10. Intranasal and sublingual delivery of inactivated polio vaccine.
Kraan H; Soema P; Amorij JP; Kersten G
Vaccine; 2017 May; 35(20):2647-2653. PubMed ID: 28400164
[TBL] [Abstract][Full Text] [Related]
11. Phase II and III Clinical Studies of Diphtheria-Tetanus-Acellular Pertussis Vaccine Containing Inactivated Polio Vaccine Derived from Sabin Strains (DTaP-sIPV).
Okada K; Miyazaki C; Kino Y; Ozaki T; Hirose M; Ueda K
J Infect Dis; 2013 Jul; 208(2):275-83. PubMed ID: 23568174
[TBL] [Abstract][Full Text] [Related]
12. [Immunogenicity of sabin inactivated poliovirus vaccine induced by diphtheria-tetanus-acellular pertussis and Sabin inactivated poliovirus combined vaccine].
Ma Y; Qin M; Hu HQ; Ji G; Feng L; Gao N; Gu J; Xie BF; He JH; Sun MB
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Jun; 25(3):197-200. PubMed ID: 21977591
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants.
Verdijk P; Rots NY; van Oijen MG; Weldon WC; Oberste MS; Okayasu H; Sutter RW; Bakker WA
Vaccine; 2014 Sep; 32(39):4938-44. PubMed ID: 25043278
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of sabin-strain based inactivated poliovirus vaccine replacing salk-strain based inactivated poliovirus vaccine: An innovative application of different strain-IPVs replacement.
Chen H; Gao Z; Bai S; Liu X; Han S; Xiao Y; Liu F; Yu Y; Sun H; Yang X
Vaccine; 2021 Apr; 39(17):2467-2474. PubMed ID: 33810904
[TBL] [Abstract][Full Text] [Related]
15. Analyzed immunogenicity of fractional doses of Sabin-inactivated poliovirus vaccine (sIPV) with intradermal delivery in rats.
Ma L; Cai W; Sun M; Cun Y; Zhou J; Liu J; Hu W; Zhang X; Song S; Jiang S; Liao G
Hum Vaccin Immunother; 2016 Dec; 12(12):3125-3131. PubMed ID: 27558963
[TBL] [Abstract][Full Text] [Related]
16. A national reference for inactivated polio vaccine derived from Sabin strains in Japan.
Shirato H; Someya Y; Ochiai M; Horiuchi Y; Takahashi M; Takeda N; Wakabayashi K; Ouchi Y; Ota Y; Tano Y; Abe S; Yamazaki S; Wakita T;
Vaccine; 2014 Sep; 32(40):5163-9. PubMed ID: 25090648
[TBL] [Abstract][Full Text] [Related]
17. Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains.
Westdijk J; Koedam P; Barro M; Steil BP; Collin N; Vedvick TS; Bakker WA; van der Ley P; Kersten G
Vaccine; 2013 Feb; 31(9):1298-304. PubMed ID: 23313617
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and Safety of a Sabin Strain-Based Inactivated Polio Vaccine: A Phase 3 Clinical Trial.
Hu Y; Wang J; Zeng G; Chu K; Jiang D; Zhu F; Ying Z; Chen L; Li C; Zhu F; Yin W
J Infect Dis; 2019 Oct; 220(10):1551-1557. PubMed ID: 30958543
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: A novel dose sparing immunization schedule.
Anand A; Molodecky NA; Pallansch MA; Sutter RW
Vaccine; 2017 May; 35(22):2993-2998. PubMed ID: 28434691
[TBL] [Abstract][Full Text] [Related]
20. Phase 3 Trial of a Sabin Strain-Based Inactivated Poliovirus Vaccine.
Liao G; Li R; Li C; Sun M; Jiang S; Li Y; Mo Z; Xia J; Xie Z; Che Y; Yang J; Yin Z; Wang J; Chu J; Cai W; Zhou J; Wang J; Li Q
J Infect Dis; 2016 Dec; 214(11):1728-1734. PubMed ID: 27658691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]